Breaking News

CD19 CAR-T Therapy Manufactured Using Lonza’s Cocoon Platform

MOH approves Cocoon Platform to manufacture a CD19 CAR-T cell immunotherapy for Phase II clinical trial for B-cell malignancies.

By: Contract Pharma

Contract Pharma Staff

Lonza and Sheba Medical Center announced the first patient has been treated at Sheba Medical Center with a CD19 CAR-T cell immunotherapy manufactured using Lonza’s Cocoon Platform. The Cocoon Platform is an automated and functionally closed system for patient-scale cell therapy manufacturing, designed to overcome some of the manufacturing challenges of manually producing personalized medicines, including autologous CAR-T cell therapies. Sheba Medical Center and Lonza have collaborated to tra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters